Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

COSM

Cosmos Health Inc

Jun 13 • 09:40AM ET

0.4700

Dollar change -0.0076
Percentage change -1.59	%

Healthcare • Medical Distribution • Greece • NASD

Peers: VRTX OPK CERS CHEK AUPH VNDA HOOK XOMA NNVC

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.04	Insider Own	32.75%	Shs Outstand	27.20M	Perf Week	-1.05%
Market Cap	13.75M	Forward P/E	-	EPS next Y	-	Insider Trans	56.05%	Shs Float	19.66M	Perf Month	5.22%
Income	-21.33M	PEG	-	EPS next Q	-	Inst Own	9.30%	Short Float	1.07%	Perf Quarter	-2.95%
Sales	53.55M	P/S	0.26	EPS this Y	-	Inst Trans	-45.02%	Short Ratio	0.49	Perf Half Y	-40.13%
Book/sh	0.95	P/B	0.49	EPS next Y	-	ROA	-	Short Interest	0.21M	Perf Year	-25.80%
Cash/sh	0.03	P/C	17.85	EPS next 5Y	-	ROE	-	52W Range	0.28 - 1.58	Perf YTD	-29.75%
Dividend Est.	-	P/FCF	-	EPS past 5Y	28.41%	ROIC	-74.82%	52W High	-70.25%	Beta	4.21
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	6.53%	Gross Margin	7.05%	52W Low	67.80%	ATR (14)	0.04
Dividend Ex-Date	-	Current Ratio	1.05	EPS Y/Y TTM	39.81%	Oper. Margin	-25.61%	RSI (14)	53.94	Volatility	2.27% 3.18%
Employees	149	Debt/Eq	0.50	Sales Y/Y TTM	-	Profit Margin	-39.83%	Recom	1.00	Target Price	3.00
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	97.62%	Payout	-	Rel Volume	0.27	Prev Close	0.48
Sales Surprise	-11.35%	EPS Surprise	-309.09%	Sales Q/Q	-13.43%	Earnings	-	Avg Volume	427.64K	Price	0.47
SMA20	2.15%	SMA50	11.37%	SMA200	-28.32%	Trades		Volume	8,721	Change	-1.59%

May-15-25 02:30PM	RETRANSMISSION - Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven (GlobeNewswire)
09:30AM	Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven (GlobeNewswire)
May-07-25 02:30PM	Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units (GlobeNewswire)
May-06-25 01:40PM	Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq (GlobeNewswire)
Apr-30-25 12:50PM	Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000 (GlobeNewswire)
12:45PM	Loading…
Apr-16-25 12:45PM	Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million (GlobeNewswire)
Apr-09-25 01:40PM	Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L (GlobeNewswire)
Apr-08-25 10:45AM	Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order (GlobeNewswire)
Feb-26-25 11:30AM	Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates (ACCESSWIRE)
Feb-18-25 08:30AM	Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1 (ACCESSWIRE)
Feb-11-25 10:15AM	Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market (ACCESSWIRE) -10.28%
Feb-10-25 01:30PM	Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market (ACCESSWIRE)
09:45AM	Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations (ACCESSWIRE)
Feb-07-25 10:00AM	Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility (ACCESSWIRE)
Feb-06-25 03:50PM	Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar (ACCESSWIRE)
11:05AM	Loading…
Feb-05-25 11:05AM	Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market (ACCESSWIRE)
Jan-28-25 11:00AM	Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow (ACCESSWIRE) -11.39%
Jan-27-25 03:50PM	Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion (ACCESSWIRE)
Jan-23-25 03:35PM	Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait (ACCESSWIRE)
Jan-22-25 08:00AM	Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million (ACCESSWIRE) -17.08%
Jan-21-25 03:00PM	Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days (ACCESSWIRE) +8.47%
Jan-14-25 09:41AM	Cosmos Health secures exclusive distribution agreement with Virax Biolabs (TipRanks) +12.55%
Jan-13-25 09:20AM	Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries (ACCESSWIRE)
Dec-26-24 01:30PM	Cosmos Health Strengthens RandD Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology (ACCESSWIRE)
01:30PM	Cosmos Health Strengthens R&D Leadership and Innovation with the Appointment of Professor Dimitrios Trafalis, MD, as Head of Oncology (ACCESSWIRE)
Dec-23-24 09:25AM	Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000 (ACCESSWIRE) +6.02%
Nov-26-24 09:30AM	Taglich Brothers Releases Updated Coverage on Cosmos Health: Projects Positive EPS for 2025 and Sets $3 Price Target, Nearly 300% Above Current Share Price (ACCESSWIRE)
Nov-18-24 08:00AM	Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets (ACCESSWIRE) +11.13%
Nov-15-24 10:20AM	Cosmos Health Reports Q3 2024 Results: Resilient Revenue and Gross Profit Amid 18.6% Expense Reduction; Stockholders' Equity Up 8.8% to $35M (ACCESSWIRE)
Nov-12-24 12:00PM	Cosmos Health Issues Letter to Shareholders (ACCESSWIRE) +7.09%
12:30PM	Loading…
Nov-01-24 12:30PM	Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21% (ACCESSWIRE) -5.32%
Sep-25-24 09:25AM	Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands (ACCESSWIRE) -10.27%
Sep-23-24 12:55PM	Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins (ACCESSWIRE) -8.18%
09:00AM	Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits (ACCESSWIRE)
Sep-19-24 03:40PM	Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion (ACCESSWIRE)
Sep-18-24 01:30PM	Cosmos Health Releases 2024-2027 Updated Guidance; Projects Revenue of $155.8M and Adjusted EBITDA of $29.4M Annually by 2027, Driven by Strategic Focus on High-Margin Segments (ACCESSWIRE)
Sep-17-24 11:45AM	Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price (ACCESSWIRE) +13.43%
Sep-16-24 08:30AM	Virax Biolabs Announces Extension of Existing Exclusive Distribution Agreement to Market Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits with Cosmos Health Inc. (PR Newswire)
08:30AM	Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar (ACCESSWIRE)
Aug-23-24 09:35AM	Cosmos Health Regains Full Compliance with Nasdaq Listing Requirements (ACCESSWIRE)
Aug-21-24 10:20AM	Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox (formerly Monkeypox) Virus Real-Time PCR Detection Kits (ACCESSWIRE) +17.76%
Aug-20-24 12:20PM	Cosmos Health Reports Q2 2024 Results: Sustains Positive Momentum with 7% Revenue Growth vs. Q1 2023 and 12.5% vs. H1 2023 (ACCESSWIRE) -15.08%
09:00AM	Cosmos Health Reports Q1 2024 Results: Continues to Deliver Strong Growth and Improved Performance with 18% YoY Revenue Increase and 39% Rise in Gross Profit (ACCESSWIRE)
Aug-08-24 01:00PM	Cosmos Health Completes Registration Process in Germany to Commence Sales of its C-Scrub Antimicrobial Wash; Enters $750M+ Market (ACCESSWIRE)
Aug-06-24 09:00AM	Cosmos Health Reports Full Year 2023 Results: Revenue Increases to $53.4M, or 6% YoY; Stockholders' Equity Remains Near Record Highs at $36M, or $2.25 per Share (ACCESSWIRE) +15.00%
Jul-25-24 02:45PM	Cosmos Health Successfully Submits Tender for C-Scrub Wash Chlorhexidine 4% to Supply NHS Scotland (ACCESSWIRE) +5.79%
11:40AM	Cosmos Health Signs Distribution Agreement with ProMed Trading for Its Sky Premium Life Food Supplements in Qatar (ACCESSWIRE)
Jul-24-24 10:55AM	Cosmos Health Updates on Contract Manufacturing Division; Completes Phase I of Production Capacity Expansion, Positioned to Generate Over $10M in Annual Gross Profit at Full Capacity (ACCESSWIRE)
Jul-19-24 11:40AM	Cosmos Health Regains Compliance with Nasdaq Minimum Bid Price Rule (ACCESSWIRE)
Jul-18-24 03:45PM	Cosmos Health's Cana Secures Additional Contract Manufacturing Agreement with Provident Pharmaceuticals for 700,000 Units, Bringing Total Order Book to 5.02 Million Units (ACCESSWIRE) -10.36%
Jul-10-24 03:45PM	Cosmos Health Advances Commercialization of CCX0722 Weight Management Solution with Completion of Pilot Production and Scale-Up Phases; Significant Step Towards Entering $143Bn Global Market (ACCESSWIRE)
Jul-09-24 02:00PM	Cosmos Health's Cana Secures Contract Manufacturing Agreement with Australia's Humacology for up to 500,000 CBD Units Annually (ACCESSWIRE)
Jul-03-24 01:05PM	Cosmos Health's Cana Laboratories Completes Facility Upgrades and Secures Contract Manufacturing Agreement with Provident Pharmaceuticals for 4.32 Million Vials of DE3-SOLE (ACCESSWIRE) -10.89%
Jul-02-24 03:30PM	Cosmos Health Expands Collaboration with Papaellinas in Cyprus; Sky Premium Life Sales Expected to More Than Double to 150,000 Units Over Next 12 Months (ACCESSWIRE) -8.18%
Jul-01-24 11:20AM	Cosmos Health Signs Distribution Agreement with ZENDON s.r.o. in Slovakia, Hungary, Poland, and Czechia for Its Sky Premium Life Nutraceutical Products; Gains Access to More than 6,000 Stores of Leading Pharmacy and Retail Chains (ACCESSWIRE) +5.77%
Jun-28-24 08:12AM	Why Is Cosmos Health (COSM) Stock Up 65% Today? (InvestorPlace) +53.17%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jun-27-24 03:45PM	Cosmos Health Signs Exclusive Distribution Agreement with Pharmalink for Its Sky Premium Life Nutraceuticals in the UAE; Receives Initial Purchase Order for 130,000 Units (ACCESSWIRE) +5.27%
Jun-18-24 10:00AM	Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent (ACCESSWIRE)
Jun-13-24 09:25AM	Cosmos Health Completes Acquisition of Pelofarm's Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million (ACCESSWIRE)
May-24-24 04:30PM	Cosmos Health Receives Additional Delinquency Letter from Nasdaq Regarding Late Filings of Its Forms 10-K and 10-Q (ACCESSWIRE) +5.87%
May-17-24 10:15AM	Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand (ACCESSWIRE)
Apr-30-24 09:42AM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Healthcare Stocks (InvestorPlace)
Apr-19-24 04:30PM	Cosmos Health Receives Nasdaq Notice on Late Filing of Its Form 10-K (ACCESSWIRE) -20.39%
Mar-21-24 09:45AM	Cosmos Health Commences Development of Cloudscreen 2.0, the New Iteration of its Next Generation AI Drug Repurposing Platform (ACCESSWIRE) -7.78%
Mar-19-24 10:10AM	Cosmos Health To Receive Regulatory Approval for C-Scrub Disinfectant in the UK, Obtains Initial Purchase Order; Explores Opportunities Outside EU, Eyeing Global $36Bn+ Market (ACCESSWIRE)
Mar-18-24 09:25AM	Cosmos Health Receives Regulatory Approval to Sell Sky Premium Life Products in $1.9Bn UAE Nutritional Supplements Market; Secures Initial Purchase Orders (ACCESSWIRE) -5.34%
Feb-29-24 09:25AM	Cosmos Health Successfully Completes Acquisition of Pharmatrade's Assets; Expects to Increase FY 2024 Annual Revenue by over $5 Million (ACCESSWIRE)
Feb-23-24 12:00AM	As Trading Frenzies Grip Penny Stocks, Criticism of Nasdaq Grows (The Wall Street Journal)
Feb-21-24 11:50AM	Taglich Brothers Publishes First Coverage Report on Cosmos Health with a Price Target of $4, a Nearly Five-Fold Increase from Current Share Price (ACCESSWIRE)
09:30AM	Taglich Brothers Initiates Coverage of Cosmos Health Inc. (GlobeNewswire)
Feb-20-24 09:25AM	Cosmos Health CEO, Greg Siokas, Purchases Shares in the Open Market, Showcasing His Confidence in the Company (ACCESSWIRE)
Feb-01-24 09:25AM	Taglich Brothers Initiates Coverage of Cosmos Health Inc. (ACCESSWIRE)
Jan-23-24 01:05PM	Cosmos Health Completes Acquisition of Cloudscreen, a Cutting-Edge AI Platform; Enters Lucrative $25Bn+ Global Drug Repurposing Market (ACCESSWIRE)
Jan-18-24 09:25AM	Cosmos Health Bolsters Presence in $400Bn+ Global Generic Drugs Market with $3.5M Acquisition of 10-Drug Portfolio (ACCESSWIRE)
Dec-27-23 09:27AM	Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023 (ACCESSWIRE) +10.07%
Dec-20-23 09:15AM	Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X (ACCESSWIRE) -12.33%
Dec-18-23 09:15AM	Cosmos Health Announces Open Market Stock Purchases by the CEO (ACCESSWIRE) +8.49%
Dec-08-23 12:45PM	Cosmos Health to Participate at Capital Links 'Invest in Greece' Forum in New York (ACCESSWIRE) -7.89%
Dec-07-23 09:35AM	Cosmos Health Enters into Agreement to Acquire Rights for WIPO-Filed Patent on Drug Targeting CNS Cancers (ACCESSWIRE) +11.76%
Dec-01-23 10:25AM	Cosmos Health Announces Patent Filing for its Obesity and Weight Management Product (ACCESSWIRE) +8.65%
Nov-21-23 09:00AM	Cosmos Health Reports Q3 2023 Results; Revenue Increased 7% YoY, Total Assets Reached Record $71.5M with Stockholders' Equity of $44.2M or $3.4/Share (ACCESSWIRE) -6.36%
Oct-11-23 09:35AM	Cosmos Health to Acquire Cloudscreen, a Cutting-Edge AI-Powered Drug Repurposing Platform; Anticipated to Establish Cosmos as a Leader in the $25Bn Global Market and Deliver Unparalleled Returns for Shareholders (ACCESSWIRE) +12.71%
Oct-05-23 08:30AM	COSMOS HEALTH CEO Issues Letter to Shareholders (ACCESSWIRE)
Sep-27-23 10:30AM	Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company (ACCESSWIRE) -13.16%
Sep-26-23 11:00AM	Cosmos Health Announces Expansion of Its C-Sept Brand with the Launch of C-Scrub Wash; Capitalizing on $29 Billion Global Antiseptic and Disinfectant Market (ACCESSWIRE) +9.83%
Sep-22-23 12:50PM	Cosmos Health Announces Relaunch of bio-bebe, its Proprietary Organic Infant Care & Nutrition Brand; Aims to Penetrate $103bn Global Baby Food Market (ACCESSWIRE)
Sep-20-23 11:50AM	Cosmos Health Announces Strategic Collaboration with C.A.PAPAELLINAS Group (ACCESSWIRE)
Sep-13-23 08:30AM	Cosmos Health Starts Stock Buyback Program (ACCESSWIRE)
08:00AM	BestGrowthStocks.com issues New Growth Report on Cosmos Health (News Direct)
Sep-12-23 08:30AM	Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023 (ACCESSWIRE) +34.34%
Aug-15-23 07:00AM	Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04 (ACCESSWIRE)
Aug-08-23 09:20AM	Cosmos Health Appoints Big 4 Accounting Firm KPMG as Auditor (ACCESSWIRE)
Aug-02-23 01:15PM	Cosmos Health Continues to Expand Mediterranation Brand, Welcomes Eleonas and Olympus Mons; Boosts Exports and Secures Purchase Orders, Including from Leading Multinational Health Food Chain (ACCESSWIRE) -14.97%
Jul-25-23 09:25AM	Cosmos Health Provides Update on Recent Developments, Maintains Strong Financial Position, Reaffirms Commitment to Growth, and Highlights CEO's Continued Investment Now Exceeds $15 Million (ACCESSWIRE)
07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-21-23 04:00PM	Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -6.35%
Jul-20-23 08:00AM	Cosmos Health Inc. Announces Pricing of $5.25 Million Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -23.39%
Jul-06-23 09:20AM	Cosmos Health Successfully Completes Acquisition of Cana Laboratories; Anticipates to Record a Substantial Gain on Bargain Purchase (ACCESSWIRE)
Jun-29-23 09:30AM	Cosmos Health Launches Chios Island, the Latest Addition to Its Mediterranation Premium Line of Supplements (ACCESSWIRE)

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Siokas Grigorios	Chief Executive Officer	May 23 '25	Buy	0.45	34,004	15,217	6,158,884	May 27 09:33 AM
Siokas Grigorios	Chief Executive Officer	May 22 '25	Buy	0.44	141,825	62,800	6,124,880	May 23 12:18 PM
Siokas Grigorios	Chief Executive Officer	May 21 '25	Buy	0.47	174,172	82,000	5,983,055	May 22 10:33 AM
Siokas Grigorios	Chief Executive Officer	May 20 '25	Buy	0.45	147,563	65,961	5,808,883	May 21 10:20 AM
Siokas Grigorios	Chief Executive Officer	May 19 '25	Buy	0.43	79,254	34,000	5,661,320	May 20 09:51 AM
Siokas Grigorios	Chief Executive Officer	Apr 24 '25	Buy	0.40	254,618	102,000	5,582,066	Apr 28 10:49 AM
Siokas Grigorios	Chief Executive Officer	Apr 24 '25	Buy	0.40	177,234	71,000	5,327,448	Apr 25 10:07 AM
Siokas Grigorios	Chief Executive Officer	Apr 23 '25	Buy	0.40	205,000	82,000	5,150,214	Apr 24 09:48 AM
Siokas Grigorios	Chief Executive Officer	Apr 22 '25	Buy	0.36	175,000	63,000	4,945,214	Apr 23 10:43 AM
Siokas Grigorios	Chief Executive Officer	Apr 21 '25	Buy	0.32	654,912	208,000	4,770,214	Apr 22 09:59 AM
Siokas Grigorios	Chief Executive Officer	Mar 04 '25	Buy	0.53	85,714	45,000	4,115,302	Mar 05 11:05 AM
Siokas Grigorios	Chief Executive Officer	Mar 03 '25	Buy	0.49	132,572	65,000	4,029,588	Mar 04 12:32 PM
Siokas Grigorios	Chief Executive Officer	Feb 24 '25	Buy	0.56	354,296	200,000	3,897,016	Feb 25 09:49 AM
Siokas Grigorios	Chief Executive Officer	Jan 30 '25	Buy	0.66	51,414	34,000	4,255,103	Jan 31 09:46 AM
Siokas Grigorios	Chief Executive Officer	Jan 22 '25	Buy	0.77	38,900	30,000	4,203,689	Jan 23 09:39 AM
Siokas Grigorios	Chief Executive Officer	Jan 17 '25	Buy	0.86	29,158	25,000	4,164,789	Jan 21 09:35 AM
Siokas Grigorios	Chief Executive Officer	Jan 16 '25	Buy	0.83	47,904	40,000	4,135,631	Jan 17 09:00 AM
Siokas Grigorios	Chief Executive Officer	Jan 15 '25	Buy	0.80	62,500	50,000	4,087,727	Jan 16 08:45 AM
Siokas Grigorios	Chief Executive Officer	Jan 14 '25	Buy	0.69	87,247	60,000	4,025,227	Jan 15 09:00 AM
Siokas Grigorios	Chief Executive Officer	Jan 13 '25	Buy	0.61	163,666	100,000	3,937,980	Jan 14 08:24 AM
Terzis Georgios	Chief Financial Officer	Dec 20 '24	Buy	0.58	85,778	50,000	727,263	Dec 26 05:27 PM
Siokas Grigorios	Chief Executive Officer	Dec 20 '24	Buy	0.58	257,334	150,000	3,774,314	Dec 26 05:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

COSM

Cosmos Health Inc

Upgrade your FINVIZ experience